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ABSTRACT
The pharmacokinetic properties of ceftazidime, a third generation cephalosporin, were investigated in 
experimentally induced febrile buffalo calves (n=5) after a single intravenous administration at a dose rate of 10 
mg/kg body weight. The fever was induced by a single/repeated intravenous injection of E. coli lipopolysaccaride 
(1 μg/kg). Ceftazidime concentrations in the plasma and urine were determined by microbiological assay. 
Ceftazidime disposition was best fi tted by a bi-compartmental open model with fi rst-order elimination. At 2.5 
min, the concentration of ceftazidime in the plasma of the febrile animals was 152.3 ± 6.77 μg/mL and the drug 
was detected up to 14 h. The elimination half-life and volume of distribution were 3.73 ± 0.42 h and 0.26 ± 0.05 
L/kg, respectively. The distribution half-life, AUC and total body clearance (ClB) were 0.24 ± 0.03 h, 217.3 ± 
23.4 μg/mL.h and 47.9 ± 4.57 mL/kg/h, respectively. Urinary excretion of ceftazidime was less than 28 percent 
after 32 h of administration of the drug in the febrile animals. An effi cacy predictor, measured as the time over 
which the active drug exceeds the bacteria minimum inhibitory concentration (T>MIC), was calculated. T>MIC 
was 73% of the recommended dosing interval (8h) for bacteria with a MIC90≤4 μg/mL. 
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Introduction
Ceftazidime is an aminothiazolyl third generation cephalosporin antimicrobial agent. 
It is active against some susceptible gram-negative bacilli (Escherichia coli, Proteus 
spp., Klebsiella spp., Enterobacter spp., Salmonella spp.), gram-positive pathogens 
(Staphylococcus spp., Streptococcus spp.) and is very active against Pseudomonas 
aeruginosa (ALBARELLOS et al., 2008). Amongst the documented reasons contributing 
to drug resistance are inappropriate dosage regimens. Rational antibiotic therapy requires 
*Corresponding author:
Suresh Kumar Sharma, B.V.Sc., A.H., M.V.Sc., PhD, Department of Veterinary Pharmacology and Toxicology, College of Veterinary 
Science, Guru Angad Dev. Veterinary and Animal Sciences University, Ludhiana - 141 004, India, Phone: + 91 161 241 4032; 
E-mail: sureshksharma@gadvasu.in
556 Vet. arhiv 82 (6), 555-565, 2012
S. K. Sharma and S. A. Ul Haq:  Pharmacokinetics of ceftazidime in febrile buffalo calves
dosage regimens to be optimized, not only for clinical effi cacy, but also to minimize 
the selection and spread of resistant pathogens. Pharmacokinetic studies of antimicrobial 
agents, which provide a basis for the determination of satisfactory dosage regimen, 
are relevant, when they are undertaken in the species in which the drugs are to be used 
clinically. There have been some limited data published on the pharmacokinetics of 
ceftazidime in animals. Pharmacokinetic data of ceftazidime has been reported in many 
animal species, including mice (KITA et al., 1992), rats (KITA et al.,1992; MATSUI et al., 
1984), rabbits (ABD-EL-ATY et al., 2001; CARBON et al., 1984; KITA et al.,1992; SAKATA et 
al., 1984), monkeys (KITA et al., 1992; MATSUI et al., 1984), calves (SOBACK and ZIV, 1989), 
sheep (RULE et al., 1991), cows (RULE et al., 1996), dogs (KITA et al., 1992; MOORE et al., 
2000; MATSUI et al., 1984) and cats (ALBARELLOS et al., 2008). The pharmacokinetics of 
chemotherapeutic agents are markedly altered in disease conditions (DARDI et al., 2005; 
SHARMA et al., 2005; TOTH et al., 1991), hence the dosage regimen obtained in healthy 
subjects cannot be extrapolated to clinical cases to treat diseased animals. Fever, which 
is one of the most common manifestations of many infectious diseases, is reported to 
induce a series of biochemical and physiological alterations in cells (MONSHOUWER 
et al., 1996). So, a study on the infl uence of fever on the pharmacokinetics of antibiotics 
is essential. The purpose of this study was to determine the pharmacokinetic variables 
of ceftazidime in febrile buffalo calves following intravenous administration. From the 
pharmacokinetic data, recommendations were made for an optimal dosage regimen of 
ceftazidime in febrile buffalo calves. 
Materials and methods
Animals. Five healthy male buffalo calves, ranging between 6-12 months of age and 
weighing between 85 and125 kg body weight, were used. The animals were housed in an 
animal shed with a concrete fl oor and adequate ventilation. The animals were determined 
to be clinically healthy before the study. All the animals were acclimatized to the animal 
shed under uniform conditions and were maintained on green fodder, wheat straw and 
water ad libitum. They did not receive any drug treatment before the study. For the 
collection of urine, the experimental animals were kept in metabolic stalls of standard size, 
from 12h before the start of experiment and for the entire study. The metabolic stalls are 
designed in such a way that urine voided by animals can be collected at any time interval 
without any spillage. Before the start of the experiment, permission for experiments on 
these animals was obtained from the Institutional Animal Ethics Committee (IAEC). 
Experimental design. Fever was induced by single/repeated intravenous administration 
of E. coli lipopolysaccaride at the dose rate of 1μg/kg b.m. (DARDI et al., 2005). Once 
fever was induced ceftazidime was injected intravenously to these fi ve animals at a dose 
rate of 10 mg/kg of ceftazidime, in a 10% solution with sterilized distilled water. Blood 
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samples (4-5 mL each) were drawn from the contralateral jugular vein into heparanized 
glass test tubes before administration and at 2.5, 5, 10, 15, 30, 45 and 60 minutes and 2, 
3, 4, 5, 6, 7, 8, 10, 12 and 14 h after administration of drug. 
Bioassay. The concentrations of ceftazidime in the plasma and urine were estimated 
by employing the microbiological assay technique (ARRET et al., 1971) using Escherichia 
coli (MTCC 739) as the test organism. Three alternate wells on assay plates were fi lled 
with reference concentration (5 μg/mL) and the remaining three with an unknown 
concentration of the drug. Three plates were used for each concentration. These assay 
plates were incubated at 37 oC for a period of 24 hours. At the end of incubation, the 
diameters of the zones of inhibition were measured and the ceftazidime concentrations 
in the samples were calculated from the standard curve and expressed as μg/mL. The 
bioassay method used in this work could not distinguish between the parent compound 
and its active metabolites, if they exist. However, it measured the overall microbiological 
activity of the drug. The standard curve of ceftazidime in buffalo calf plasma was linear 
between 1 to 5 μg/mL. The value of the coeffi cient of determination (r2) of the standard 
curve was 0.99. The drug could be detected up to a minimum limit of 1 μg/mL. The 
ceftazidime recovery exceeded 96% from plasma and urine over the concentration range 
of 5 to 200 μg/mL. The intra-day and inter-day coeffi cients of variance were less than 3%.
Pharmacokinetic analysis. The plasma concentration time data for each buffalo 
calf were determined according to the computed least squares regression technique. The 
kinetic parameters were calculated from the formulae derived for a two- compartment 
open model (GIBALDI and PERRIER, 1982). T>MIC (%) was calculated as per following 
equation (ALBARELLOS et al., 2008):
 T>MIC (%) = ln(dose/Vd  × MIC) × t1/2 ln2 × 100/inter-dose interval 
Results 
The effect of E. coli lipopolysaccharide on body temperature was recorded. The 
dose of lipopolysaccaride caused fever within 2-3 hours and fever persisted for 14 hours. 
At least 1.1 0C increase of temperature from the normal temperature was taken as the 
time of ceftazidime administration. The mean plasma concentrations of ceftazidime 
as a function of time in febrile buffalo calves were plotted on a semilogarithmic scale 
(Fig. 1). At 2.5 minutes the mean plasma concentration of ceftazidime was 152.3 ± 6.77 
μg/mL, which rapidly declined to a plasma concentration of 88.4 ± 4.07 μg/mL at 15 
minutes. The levels gradually decreased to 2.10 ± 0.37 μg/mL at 14 hours. The various 
pharmacokinetic parameters for ceftazidime in buffalo calves in which fever was induced 
before administration of drug are given in Table 1. The elimination half life (t1/2β), volume 
of distribution (Vd(area)) and total body clearance in febrile animals were 3.73 ± 0.42 h, 
0.26 ± 0.05 L/kg and 47.9 ± 4.57 mL/kg/h, respectively. The cumulative percent of the 
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total dose excreted in the urine of febrile animals (Table 2) was 27.6 ± 10.2 percent within 
32 hours. The calculated T>MIC (%) of ceftazidime for three dosing intervals (8, 12 and 
24 h) are presented in Table 3.
Time (h)
Fig. 1. A semi logarithmic plot of plasma levels of ceftazidime after a single intravenous dose of 
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Table 1. Pharmacokinetic parameters of ceftazidime in febrile buffalo calves (n=5) after a single 
intravenous injection of 10 mg/kg body weight. 
Parametera Unit Mean ± SE
Cp
o μg/mL 163.2 ± 5.87
A μg/mL 132.2 ± 5.71
B μg/mL 31.04 ± 5.27
α h-1 3.07 ± 0.32
β h-1 0.19 ± 0.02
t1/2α h 0.24 ± 0.03
t1/2β h 3.73 ± 0.42
Kel h
-1 0.23 ± 0.02
K12 h
-1 2.29 ± 0.26
K21 h
-1 0.74 ± 0.13
K12/K21 ratio - 3.66 ± 1.07
AUC μg/mL.h 217.3 ± 23.4
AUMC μg.mL-1.h2 952.9 ± 176.4
Vd(area ) L/kg 0.26 ± 0.05
Vd(SS) L/kg 0.20 ± 0.02
ClB mL/kg/h 47.9 ± 4.57
a Kinetic parameters as described by Gibaldi and Perrier (1982). Cp
o
 = plasma drug concentration immediately 
following intravenous injection of a single dose; A, B = zero-time plasma drug concentration intercepts of 
regression lines of distribution and elimination phases, respectively; α and β = distribution and elimination rate 
constants, respectively; t1/2α = distribution half life; t1/2β = elimination half life; Kel = elimination rate constant from 
central compartment; K12, K21 = rate of transfer of drug from central (blood) to peripheral (tissues) compartment 
and vice-versa; AUC = total area under plasma drug concentration-time curve; AUMC = total area under the fi rst 
moment plasma drug concentration-time curve; Vd(area) = apparent volume of distribution, based on area under 
curve; Vd(ss) = apparent volume of distribution, based on steady state plasma levels; ClB = total plasma clearance.
Table 2. Urinary excretion of ceftazidime in febrile buffalo calves following a single intravenous 















of total dose 
excreted
0-4 6.56 ± 5.93 0.59 ± 0.50 0 - 4 6.56 ± 5.94 0.59 ± 0.50
4-8 206.4 ± 89.7 22.3 ± 9.30 0 - 8 209.8 ± 92.2 22.6 ± 9.44
8-12 25.2 ± 4.57 2.85 ± 0.47 0 - 12 234.9 ± 96.6 25.4 ± 9.83
12-20 18.75 ± 1.25 2.68 ± 0.17 0 - 20 244.3 ± 95.0 26.8 ± 9.88
20-24 10.0 ± 4.67 1.47 ± 0.76 0 - 24 247.3 ± 96.1 27.2 ± 10.1
24-28 4.12 ± 0.04 0.61 ± 0.02 0 - 28 248.4 ± 95.5 27.3 ± 10.1
28-32 5.22 ± 2.37 0.77 ± 0.36 0 - 32 250.3 ± 96.1 27.6 ± 10.2
Values given are mean ± SE of the results obtained from 4-5 animals unless otherwise stated 
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Table 3. Time above ceftazidime minimum inhibitory concentration (T >MIC) expressed as 




0.1 192.4 128.3 64.1
0.25 162.8 108.5 54.3
0.3125 155.5 103.7 51.8
0.5 140.4 93.6 46.8
0.625 133.1 88.8 44.4
1 118.0 78.6 39.3
2 95.6 63.7 31.9
4 73.2 48.8 24.4
8 50.8 33.8 16.9
Discussion
Evaluation of the results of plasma ceftazidime levels against time indicated that the 
pharmacokinetics of ceftazidime in febrile buffalo calves, after intravenous administration, 
are best described by the two-compartment open model. The plasma concentration-time 
data were adequately described by the equation: 
C p = Ae
-αt + Be-βt 
where Cp is ceftazidime concentration in plasma at time ‘t’. A and B are zero time 
intercepts of the distribution and elimination phase of the plasma concentration time curve. 
α and β are the distribution and elimination rate constants, respectively, and ‘e’ represents 
the base of natural logarithm. The disposition of ceftazidime following intravenous 
injection has been reported to follow a 2-compartment open model in rats (MATSUI et al., 
1984), unweaned calves (SOBACK and ZIV, 1989), sheep (RULE et al., 1991), non-lactating 
cows (RULE et al., 1996), rabbits (ABD-EL-ATY et al., 2001) and cats (ALBARELLOS et al., 
2008). In contrast, ceftazidime followed a three compartment open model in lactating 
cows (RULE et al., 1996).
Plasma concentrations of ceftazidime after IV administration remained greater than 
2μg/mL for 14 h. A comparison of plasma levels of ceftazidime in febrile animals with 
that in healthy animals (SHAH AHSAN UL HAQ, 2010), indicated that the plasma levels 
of ceftazidime in febrile buffalo calves were almost similar to healthy buffalo calves. 
In contrast to this study, lower concentrations have been reported of cefepime in febrile 
cross-bred calves (PAWAR and SHARMA, 2008), gentamicin in febrile goats (AHMAD et 
al., 1994) and human beings (PENINGTON et al., 1975), cefazolin in febrile goats (ROY et 
al., 1992), cefuroxime (CHAUDHARY et al., 1999) and ceftriaxone (DARDI et al., 2005) in 
buffalo calves. The high values of the distribution rate constant α (3.07 ± 0.32 h-1) indicated 
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that ceftazidime is rapidly distributed into various body fl uids and tissue compartments. 
Ceftazidime shows rapid distribution refl ected by the rate constant. This process in 
buffalo calves seems to be faster than in unweaned calves (SOBACK and ZIV, 1989), but 
slower than in lactating and non- lactating cows (RULE et al., 1996), dogs (MATSUI et al., 
1984) and cats (ALBARELLOS et al., 2008). The rapid distribution of ceftazidime is further 
substantiated by the high values of K12/K 21 (3.66 ± 1.07). The elimination half-life of 
ceftazidime in febrile animals (3.73 ± 0.42 h) is similar to that reported in healthy (3.42 
± 0.21 h) animals (SHAH AHSAN UL HAQ, 2010), but longer than the values reported in 
unweaned calves (SOBACK and ZIV, 1989), sheep (RULE et al., 1991), dogs and mice (KITA 
et al., 1992), lactating and non-lactating cows (RULE et al., 1996), rabbits (ABD-EL-ATY et 
al., 2001) and cats (ALBARELLOS et al., 2008). 
The volume of distribution at steady state (Vd(ss)) is the constant that expresses 
the amount of the drug in the body at steady state as a proportion of the corresponding 
expected plasma concentration at steady state (TOUTAIN and BOUSQUET-MELOU, 2004). 
The relatively low volume of distribution at steady state in febrile buffalo calves (0.2 ± 
0.02 L/kg) was as expected for a beta lactam antibiotic. This value was consistent with 
that reported in healthy buffalo calves (SHAH AHSAN UL HAQ, 2010), dogs (MATSUI et 
al., 1984) and cats (ALBARELLOS et al., 2008), but, was smaller than reported in unweaned 
calves (SOBACK and ZIV, 1989), sheep (RULE et al., 1991), lactating and non-lactating cows 
(RULE et al., 1996). The value of Vd(ss) in healthy buffalo calves, dogs, cats, unweaned 
calves, sheep, lactating and non-lactating cows was 0.18 ± 0.01, 0.21 ± 0.0007, 0.18 ± 
0.04, 0.29 ± 0.06, 0.35 ± 0.21, 0.49 ± 0.14 and 0.39 ± 0.21 L/kg, respectively.
While comparing the total body clearance in febrile animals with that of healthy 
animals (SHAH AHSAN UL HAQ, 2010), it was found that the value of ClB in febrile animals 
(47.9 ± 4.57 mL/kg/h) is not signifi cantly different as compared to healthy animals (39.5 
± 1.15 mL/kg/h). Endotoxin causes hepatic and renal dysfunction (WILKINSON, 1977) as 
well as hemodynamic depression (VAN MIERT, 1973). Due to the signifi cant alterations 
in hepatic function, the levels of various enzymes, responsible for the metabolism of 
these antimicrobials, are altered and change the elimination and biotransformation 
pattern of the drug during fever (SINGH et al., 1997). Since ceftazidime is not signifi cantly 
metabolized, is excreted unchanged primarily in urine by the glomerular fi lteration 
process (ALBARELLOS et al., 2008; SOBACK and ZIV, 1989) and is poorly bound to plasma 
proteins, this may be the reason why febrile conditions did not affect the pharmacokinetics 
of ceftazidime. 
Ceftazidime is mostly eliminated by glomerular fi ltration (ALBARELLOS et al., 2008; 
SOBACK and ZIV, 1989). The cumulative percent of total dose excreted in the urine of 
febrile animals was 27.6 ± 10.2 percent within 32 hours. In contrast to our fi ndings, the 
cumulative percent of ceftazidime excreted in the urine of rats and dogs (MATSUI et al., 
1984) and mice (KITA et al., 1992) was 97.1, 86.3 and 77.9 percent, respectively. The peak 
urine level of the drug (410.9 ± 89.1 μg/mL) was detected at 8 h and there after the level 
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remained at ≥10μg/mL in the urine up to 32 hours from administration. The concentration 
of ceftazidime in the urine of buffalo calves remained higher than the MIC (0.25 to 8 μg/
mL) of most microorganisms (ALBARELLOS et al., 2008; MOORE et al., 2000; SOBACK 
and ZIV, 1989) sensitive to the drug up to 32h. This suggested that use of ceftazidime in 
buffalo calves might achieve successful bacterial killing in urinary tract infections caused 
by microorganisms having susceptibility of ≤10 μg/mL. 
In recent years, substantial efforts have been devoted to elucidating systematically 
the dynamic relationship between pharmacokinetic and pharmacodynamic variables. 
The main concept of this pharmacokinetic-pharmacodynamic approach is to use the 
concentration-effect relationship of the drug of interest in dosage adjustment and product 
development in a logical way, and minimize trial-and-error approaches (MEIBOHM and 
DERENDORF, 1997). Accordingly, several effi cacy indices or surrogate markers that 
take both pharmacokinetic and pharmacodynamic information into account have been 
defi ned and used to describe the antibacterial activity of various classes of antimicrobial 
agents (HYATT et al., 1995; SANCHEZ-RECIO et al., 2000). In these approaches, the 
pharmacokinetic parameter is usually the serum concentration of the anti-infective agent, 
and the pharmacodynamic parameter is almost exclusively the MIC (SCHENTAG, 1999a 
and 1999b). Various empirical pharmacokinetic/pharmacodynamic indices have been 
proposed (ALIABADI and LEES, 2000; HYATT et al., 1995) to predict the success or failure 
of therapy. Three appear to be suffi cient to predict drug effectiveness: T >MIC (therapeutic 
time) when antibiotics are time-dependent, AUIC (AUC/MIC), and Cmax/MIC (inhibitory 
ratio) when antibiotics are concentration-dependent. For β-lactam antibiotics, the most 
important pharmacokinetic- pharmacodynamic index correlating with in vivo effi cacy has 
been shown to be the duration that the unbound concentration of an antibiotic remains 
above the MIC as a percentage of the dosing interval (%T>MIC) (ANDES and CRAIG 
2002; CRAIG 1998). For cephalosporins, a T >MIC 35-40% of the inter dose interval 
has been established as optimal for bacteriostatic action, while a T >MIC of 60-70% is 
necessary for bactericidal effect (CRAIG, 1998; TOUTAIN et al., 2002). The MIC values 
of ceftazidime are 0.25 μg/mL for E. coli, 4 μg/mL for Pseudomonas aeruginosa and 8 
μg/mL for Staphylococcus spp. for human and animal strains (ALBARELLOS et al., 2008; 
MOORE et al., 2000; SOBACK and ZIV, 1989). There is no published information regarding 
ceftazidime MIC’s against the most important pathogens isolated from buffalo calves. In 
this study, ceftazidime administrations at a dose of 10 mg/kg seem to be equally suitable 
for the inter-dose intervals proposed (8 h) against bacterial isolates with MIC ≤ 4μg/
mL. Furthermore, clinical controlled trials are mandatory to establish proper ceftazidime 
dosing schedules in this species.
In conclusion, on the basis of the results reported above, ceftazidime (10 mg/kg) shows 
favorable pharmacokinetic behavior in febrile buffalo calves, but needs to be evaluated 
for clinical effi cacy and safety in buffalo species before issuing fi nal recommendations. 
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It would appear to be a good therapeutic tool for the treatment of most of the infections 
produced by Gram-negative and Gram-positive susceptible bacteria in buffalo calves. 
_______
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SAŽETAK 
Farmakokinetička svojstva ceftazidima, cefalosporinskog antibiotika treće generacije, istražena su u 
febrilne bivolske teladi (n=5) nakon njegove jednokratne intravenske primjene u dozi od 10 mg/kg tjelesne 
mase. Vrućica je u teladi bila pokusno izazvana jednokratnim odnosno ponovljenim intravenskim davanjem 
lipopolisaharida bakterije E. coli u dozi od 1 mg/kg. Koncentracija ceftazidima u plazmi i mokraći određena 
je mikrobiološkim postupkom. Farmakokinetičko ponašanje ceftazidima u febrilnih životija opisano je u dva 
modela. Za 2,5 minuta koncentracija ceftazidima u plazmi febrilnih životinja iznosila je 152,3 ± 6,77 μg/mL, a 
lijek se mogao dokazati sve do 14 sati nakon primjene. Poluvrijeme njegova izlučivanja iznosilo je 3,73 
± 0,42 h, a količina raspodjele 0,26 ± 0,05 L/kg. Poluvrijeme njegove raspodjele bilo je 0,24 ± 0,03 h, 
površine ispod koncentracijske krivulje u plazmi 217,3 ± 23,4 μg/mL.h, a ukupni klirens iz organizma 
47,9 ± 4,57 mL/kg/h. Izlučivanje ceftazidima mokraćom bilo je manje od 28% nakon 32 sata od primjene. 
Predviđena učinkovitost lijeka, izmjerena kao vrijeme u kojem je aktivna supstancija bila iznad minimalne 
inhibicijske koncentracije (T>MIC), bila je 73% od preporučenog razmaka primjene (8h) za bakterije s MIC90≤4 
μg/mL.
Ključnee riječi: bivolska telad, ceftazidim, doziranje, vrućica, farmakokinetika________________________________________________________________________________________
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